Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 5, 2016, Pages 1031-1036

  Hiraoka, Atsushi ^a   Kumada, Takashi ^b   Michitaka, Kojiro ^a   Toyoda, Hidenori ^b   Tada, Toshifumi ^b   Ueki, Hidetaro ^a   Kaneto, Miho ^a   Aibiki, Toshihiko ^a   Okudaira, Tomonari ^a   Kawakami, Takamasa ^a   Kawamura, Tomoe ^a   Yamago, Hiroka ^a   Suga, Yoshifumi ^a   Miyamoto, Yuji ^a   Tomida, Hideomi ^a   Azemoto, Nobuaki ^a   Mori, Kenichiro ^a   Miyata, Hideki ^a   Ninomiya, Tomoyuki ^a   Kawasaki, Hideki ^a  

^a EHIME PREFECTURAL CENTRAL HOSPITAL   (Japan)

^b OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

ALBI grade; Hepatocellular carcinoma; JIS score; Prognosis; Scoring system

Indexed keywords

ALBUMIN; ANTINEOPLASTIC AGENT; BILIRUBIN; ALB PROTEIN, HUMAN; SERUM ALBUMIN; TUMOR MARKER;

AGED; ALBUMIN BILIRUBIN GRADE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL EVALUATION; FEMALE; HUMAN; JAPANESE (PEOPLE); LIVER CELL CARCINOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICAL PARAMETERS; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; BLOOD; CANCER GRADING; COMPARATIVE STUDY; JAPAN; KAPLAN MEIER METHOD; LIVER FUNCTION TEST; LIVER TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; RISK FACTOR; TIME FACTOR;

AGED; BILIRUBIN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; TIME FACTORS;

EID: 84964490265     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13250     Document Type: Article

References (30)

1. Kudo M, Chung H, Osaki Y. Prognostic scoring system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003; 38: 207-15.
2. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
3. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-38.
4. Toyoda H, Kumada T, Osaki Y et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin. Gastroenterol. Hepatol. 2006; 4: 1528-36.
5. Pugh RN, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 1973; 60: 646-9.
6. th edn, 2009; 24-7.
7. Johnson PJ, Berhane S, Kagebayashi C et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 2015; 33: 550-8.
8. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for treatment of small hepatocellular carcinoma in patients with cirrhosis. N. Eng. J. Med. 1996; 334: 693-9.
9. Arii S, Yamaoka Y, Futagawa S et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
10. Ikai I, Arii S, Kojiro M et al. Reevaluation of Prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802.
11. Tateishi R, Shiina S, Teratani T et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. an analysis of 1000 cases. Cancer 2005; 103: 1201-9.
12. Hiraoka A, Michitaka K, Horiike N et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J. Gastroenterol. Hepatol. 2010; 25: 403-7.
13. Takayasu K, Arii S, Ikai I et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
14. Nagamatsu H, Hiraki M, Mizukami N et al. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment. Pharmacol. Ther. 2010; 32: 543-50.
15. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan. World J. Gastroenterol. 2006; 12: 828-9.
16. Kudo M, Izumi N, Kokudo N et al. HCC Expert Panel of Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig. Dis. 2011; 29: 339-64.
17. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
18. Hiraoka A, Hiasa Y, Onji M, Michitaka K. New contrast enhanced ultrasonography agent: impact of Sonazoid on radiofrequency ablation. J. Gastroenterol. Hepatol. 2011; 26: 616-8.
19. Hiraoka A, Hidaka S, Shimizu Y et al. Recent trends of Japanese hepatocellular carcinoma due to HCV in aging society. Hepatogastroenterol. 2012; 59: 1893-5.
20. Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J. Gastroenterol. 2008; 43: 967-74.
21. Aleman S, Rahbin N, Weiland O et al. A risk for hepatocellular carcinoma patients long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. Clin. Infect. Dis. 2013; 57: 230-6.
22. Toyoda H, Tada T, Tsuji K et al. Characteristics and Prognosis of Hepatocellular Carcinoma Detected in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus: a Multicenter Study from Japan. Hepatol. Res. 2015 Oct 27. DOI:10.1111/hepr.12613. [Epub ahead of print]
23. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083-91.
24. Omata M, Nishiguchi S, Ueno Y et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J. Viral Hepat. 2014; 21: 762-8.
25. Mizokami M, Yokosuka O, Takehara T et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect. Dis. 2015; 15: 645-53.
26. Kudo M, Chung H, Haji S et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with CLIP score. Hepatology 2004; 40: 1396-1405.
27. Tateishi R, Yoshida H, Shiina S et.al. Proposal of a new prognostic model for hepatocellular carcinoma: an analysis of 403 patients. Gut 2005; 54: 419-425.
28. Hiraoka A, Horiike N, Yamashita Y et al. Risk factors for death in 224 cases of hepatocellular carcinoma after transcatheter arterial chemoembolization. Hepatogastroenterol. 2009; 56: 213-7.
29. Zhang BH, Wang XH, Yue HY, Ling CQ. A new staging system is more discriminant than conventional staging systems for unresectable hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2010; 136: 821-7.
30. Hiraoka A, Ishimaru Y, Kawasaki H et al. Tumor markers AFP, AFP-L3, and DCP in hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Oncology 2015; 89: 167-74.